Alnylam announces top-line results of Phase IIb trial of ALN-RSV01
Alnylam announced top-line results from a Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus infection in lung transplant patients. The primary endpoint of the study was the …
